Do you think in aptamers?
Think in AptusBiotech

Do you think in aptamers? Think in AptusBiotech


AptusBiotech is a biotech start-up SME founded in 2010 from a collaboration agreement with the Ramon y Cajal Hospital Foundation (FIBio-HRC).

Our goal is to become a leading company in the development of new biotechnological applications based on aptamers.

Aptamer technology is an innovative alternative and much less known than that of monoclonal antibodies. This technology provides multiple applications in biotechnology, health, agriculture-food industry and other sectors.

APTUS activities are focused on:

Latest News
Aptus facilities are located within the Ramón y Cajal Hospital,
Department of Biochemistry-Research.
Highlighted Projects

ApMnk Program

AptusBiotech is developing a therapeutic aptamer against MNK1b (apMNKQ2) that i) inhibits tumorigenesis, affecting proliferation and the ability to form colonies in three breast tumor lines; ii) it produces cell death, mainly through a caspase-mediated apoptotic mechanism; iii) inhibits the metastatic capacity of breast tumor cells, altering the epithelium-mesenchyme transition (TEM) and inhibiting cell migration and invasion. 


After a stroke, cell damage induced by the lack of blood supply causes the release of endogenous cell components to the neuron extracellular medium, triggering central nervous system alarms. One of the primary sensors of these brain damage-associated molecular patterns (DAMPs) is TLR4, a central receptor in innate immunity and expressed on the plasmatic membrane of immune cells such as microglia, neutrophils, monocytes, macrophages, among others.


OLIGOFASTX: Comprehensive platform for the sustainable development of Oligonucleotide-based therapies.
The OLIGOFASTX project, led by Sylentis, S.A. (Pharma Mar Group) brings together 7 Spanish companies united in order to facilitate and contribute to the accelerated development of oligonucleotide-based therapies in Spain.


PHITBAC: Nanophotonic biosensors for the diagnosis and clinical management of bacterial infections at the point-of-care (PLEC2021-007739), financed by MCIN/AEI /10.13039/501100011033 as well as European Union NextGenerationEU/ PRTR.

PHITBAC aims to significantly contribute to these next-generation diagnostics by introducing a new, disruptive, and versatile point-of-care nanobiosensor technology for the whole diagnosis and clinical management of bacterial infectious diseases.